Evidence map›Paper›PMID 39249161›Full record

ArticleJournal of cancer research and clinical oncology2024

Paclitaxel hyperthermia suppresses gastric cancer migration through MiR-183-5p/PPP2CA/AKT/GSK3β/β-catenin axis.

Xiansheng Yang, Chang Liu, Zheng Li, Juncai Wen, Jinfu He, Yunxin Lu, Quanxing Liao, Tian Wang, Hongsheng Tang, Xianzi Yang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiansheng Yang *Department of Anus and Intestine Surgery, The First People's Hospital of Foshan, Foshan, 528000, China.
Chang Liu *Medical Affair Department, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
Zheng Li *Second Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Juncai WenDepartment of Medical Oncology, Puning People's Hospital, Puning, 515300, China.
Jinfu HeSecond Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Yunxin LuState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Quanxing LiaoFirst Department of General Surgery, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, 511518, China.
Tian WangSecond Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Hongsheng TangSecond Department of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. 15913139343@163.com.
Xianzi YangDepartment of Medical Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. yangxz@gzhmu.edu.cn.
Lisi ZengAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China. zenglisi2017@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer (GC), a prevalent malignant tumor which is a leading cause of death from malignancy around the world. Peritoneal metastasis accounts for the major cause of mortality in patients with GC. Despite hyperthermia intraperitoneal chemotherapy (HIPEC) improves the therapeutic effect of GC, it's equivocal about the mechanism under HIPEC.

methodsMiR-183-5p expression was sifted from miRNA chip and detected in both GC patients and cell lines by qRT-PCR. Gene interference and rescue experiments were performed to identified biological function in vitro and vivo. Next, we affirmed PPP2CA as targeted of miR-183-5p by dual luciferase reporter assay. Finally, the potential relationship between HIPEC and miR-183-5p was explored.

resultsMiR-183-5p is up-regulated in GC and associated with advanced stage and poor prognosis. MiR-183-5p accelerate GC migration in vitro which is influenced by miR-183-5p/PPP2CA/AKT/GSK3β/β-catenin Axis. HIPEC exerts migration inhibition via attenuating miR-183-5p expression.

conclusionMiR-183-5p can be used as a potential HIPEC biomarker in patients with CC.

Indexed as

beta CateninCell MovementGlycogen Synthase Kinase 3 betaHyperthermia, InducedMicroRNAsProto-Oncogene Proteins c-aktStomach NeoplasmsAnimalsAntineoplastic Agents, PhytogenicCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CAntineoplastic Agents, Phytogenicbeta CateninCTNNB1 protein, humanGlycogen Synthase Kinase 3 betaGSK3B protein, humanMicroRNAsMIRN183 microRNA, humanProtein Phosphatase 2Proto-Oncogene Proteins c-aktGastric cancerHIPECMigrationMiR-183-5p

Identifiers

PMID39249161
PMCPMC11383839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.